Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Two Prophylactic Schedules (Prulifloxacin Versus Phosphomycin)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01231737
Recruitment Status : Unknown
Verified October 2009 by University Of Perugia.
Recruitment status was:  Enrolling by invitation
First Posted : November 1, 2010
Last Update Posted : November 1, 2010
Sponsor:
Information provided by:
University Of Perugia

Brief Summary:

Epidemiological studies showed that 20-30% of patients with uncomplicated urinary tract infections risked recurrent infection. Urinary tract infection causes marked discomfort for the patient, has a negative impact upon quality of life, and is associated with high social and health costs in terms of specialist appointments, laboratory and instrumental tests and prescriptions . Although diverse cycles of antibiotic therapy and prophylaxis have been proposed, doubts persist about the most efficacious pharmacological agents, duration of prophylaxis , the incidence of adverse effects and relapse when antibiotic therapy is suspended.

Aims of the study:

  1. To compare the efficacy of two prophylactic schedules (Prulifloxacin vs Phosphomycin):

    • in reducing the number of urinary tract infection episodes during prophylaxis
    • in reducing the number of urinary tract infection episodes after prophylaxis
    • in improving the patient's quality of life .
  2. To assess :

    • Tolerability of antibiotic prophylaxis
    • The incidence of resistance to antibiotic therapy

Condition or disease Intervention/treatment Phase
Urinary Tract Infection Drug: prulifloxacin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 96 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Efficacy of Prulifloxacin vs Phosphomycin in the Prophylasy of Urinary Tract Infection
Study Start Date : November 2010
Estimated Primary Completion Date : February 2011
Estimated Study Completion Date : February 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Fosfomycin

Arm Intervention/treatment
Active Comparator: Prulifloxacin Drug: prulifloxacin
Prulifloxacin 1 tablet/week for 12 weeks.




Primary Outcome Measures :
  1. number of urinary tract infection episodes during prophylaxis [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. improving the patient's quality of life [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female patients
  • Age over 18 years old
  • No allergies to the drugs to be prescribed
  • No counter-indications to this drug therapy
  • Urine culture shows responsiveness to drugs at recruitment of patient
  • History of urinary tract infections with at least three episodes in the previous year or two in the past six months

Exclusion Criteria:

  • Lack of tolerability of prescribed drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01231737


Sponsors and Collaborators
University Of Perugia
Investigators
Layout table for investigator information
Study Chair: Elisabetta Costantini University Of Perugia
Layout table for additonal information
Responsible Party: University of Perugia
ClinicalTrials.gov Identifier: NCT01231737    
Other Study ID Numbers: 002
First Posted: November 1, 2010    Key Record Dates
Last Update Posted: November 1, 2010
Last Verified: October 2009
Keywords provided by University Of Perugia:
Prophylasy
recurrent urinary tract infection
prulifloxacin
phosphomycin
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Urinary Tract Infections
Urologic Diseases
Prulifloxacin
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents